Do you have any revisions/thoughts on RPRX marketcap after their Uterine Fibroids results? I realize the data confirming safety are criticial (and indications are that safety looks fine), and am wondering if that is the last item keeping the share price from taking off? Or is it the meetings with FDA prior to completing final pivital Fibroid and Endo trials?
I'm still a little puzzled by the Mr. P's statements regarding how hedge funds continue to keep a cloud over the share price... at least until the fall. Now with the money raised to finish most of the trials, another significant "risk" has been removed from the stock. You saw what happened with DNDN in terms of secondaries. It wasn't pretty.
Market Data 
Markets 
AI
